Down 24.23% ONESOURCE.NS OneSource Pharma NSE intraday 27 Jan 2026: outlook
ONESOURCE.NS stock plunged 24.23% intraday to INR 1171.60 on 27 Jan 2026 on the NSE, marking it among the top intraday losers. The drop followed heavy trading with volume at 2,098,263.00 shares versus an average of 173,556.00, lifting relative volume to 4.19. Investors reacted to earnings-call uncertainty and regulatory concerns reported in market notes, driving a sharp gap from the previous close of INR 1546.30. We break down drivers, valuation gaps, technical signals and Meyka AI model forecasts to frame near-term trade and risk views for OneSource Specialty Pharma Ltd. (ONESOURCE.NS).
ONESOURCE.NS stock intraday move
The stock fell 24.23% to INR 1171.60 on 27 Jan 2026, down INR 374.70 from the previous close of INR 1546.30. Volume spiked to 2,098,263.00 versus an average volume of 173,556.00, signaling heavy selling pressure and liquidation activity.
Drivers and news feeding the decline
Market reports pointed to uncertainties in the recent Q3 earnings call and regulatory approval timing that could delay revenue recognition and near-term guidance. The commentary mirrored an investing.com summary of the Q3 2026 earnings call that flagged regulatory risks and guidance uncertainty, which likely amplified intraday selling source.
Valuation and fundamentals for ONESOURCE.NS stock
OneSource Specialty Pharma (ONESOURCE.NS) trades at PE 831.40 with EPS INR 1.72 and PB 2.76, suggesting the market prices a steep premium against current earnings. Key ratios show price-to-sales 23.31 and EV/EBITDA 87.70, while book value per share is INR 518.08, indicating valuation tension relative to healthcare biotech peers where average PB is near 4.62 and average PE near 38.54 in the sector.
Technical picture and price structure
Price opened at INR 1400.00, hit a day high INR 1409.40 and a day low INR 1160.00, with the session close at INR 1171.60. Short-term indicators show RSI 54.06 and MACD histogram positive but shrinking, while the 50-day average is INR 1690.59 and the 200-day average is INR 1808.03, pointing to a longer-term downtrend with a short-term bounce potential.
Meyka AI grade and model outlook for ONESOURCE.NS stock
Meyka AI rates ONESOURCE.NS with a score of 62.89 out of 100 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly target INR 1225.85, a quarterly INR 1412.71, and a yearly INR 1672.24; these imply a near-term upside of 4.63%, a 3-month upside of 20.59%, and a 12-month upside of 42.79% versus the current price INR 1171.60. Forecasts are model-based projections and not guarantees.
Risks, sector context and trading checklist
Key risks include regulatory delays, long receivables and inventory cycles (days sales outstanding 344.91, days inventory 575.29) and weak cash conversion. Sector context: healthcare biotech in India shows higher volatility and longer product approval timelines, so position sizing, stop-loss discipline and monitoring of upcoming regulatory updates are essential for active traders and investors.
Final Thoughts
ONESOURCE.NS stock’s intraday fall of 24.23% to INR 1171.60 on 27 Jan 2026 reflects a sharp market reaction to earnings-call uncertainty and regulatory timing concerns. Trading volume jumped to 2,098,263.00, well above the average 173,556.00, confirming distribution. Valuation metrics remain stretched with PE 831.40 and price-to-sales 23.31, but Meyka AI’s model offers a counterpoint: a 12-month forecast of INR 1672.24, implying ~42.79% upside from current levels. That gap underlines the binary nature of the trade: a successful regulatory update or revenue beat could validate upside, while further delays will pressure multiples. Our view: treat ONESOURCE.NS as a high-volatility, event-driven security. Traders should use tight risk limits and monitor regulatory updates; longer-term investors should await clearer cash-flow improvements and earnings quality before adding exposure. Forecasts are model-based projections and not guarantees.
FAQs
Why did ONESOURCE.NS stock drop sharply today?
The drop followed Q3 earnings-call concerns and regulatory uncertainty that could delay revenue recognition. Heavy volume of 2,098,263.00 shares amplified the move, signalling broad selling pressure on ONESOURCE.NS stock.
What valuation metrics matter for ONESOURCE.NS stock?
Key metrics are PE 831.40, PB 2.76, price-to-sales 23.31 and book value per share INR 518.08. These show a stretched earnings multiple versus biotech peers and highlight valuation risk for ONESOURCE.NS stock.
What is Meyka AI’s forecast for ONESOURCE.NS stock?
Meyka AI’s forecast model projects monthly INR 1225.85, quarterly INR 1412.71, and yearly INR 1672.24, implying a 12‑month upside near 42.79% versus INR 1171.60. Forecasts are model-based and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
